Home 主打产品 植物提取物 天然提取物 产品目录 产品解决方案 展会 联系我们
藤茶提取物二氢杨梅素 Dihydromyricetin
杨梅素 Myricetin
木犀草素Luteolin
苦杏仁甙amygdalin
绿原酸Chlorogenic acid
芹菜素apigenin
厚朴提取物Magnolia bark extract
厚朴酚magnolol
和厚朴酚Honokiol
厚朴总酚magnolol+honokiol
博落回提取物Macleaya cordata extract
血根碱sanguinarine
白屈菜红碱Chelerythrine
迷迭香提取物rosemary leaf extract
迷迭香酸rosmarnic aicd
鼠尾草酸Carnosic acid
熊果酸Ursolic acid
鼠尾草酸油carnosic acid liquid oil
绿咖啡豆提取物green coffee bean extract
金银花提取物honeysuckle flower extract
巴拿巴叶提取物Banaba leaf extract
枇杷叶提取物Loquat leaf extract
漆黄素Fisetin
虎杖甙Polydatin
芒果甙mangiferin
白桦脂醇Betulin
石杉碱甲huperzine a
阿魏酸Ferulic acid
白藜芦醇Resveratrol

漆黄素Fisetin 

漆黄素

品名: 黄栌提取物
形式: 粉末
外观 : 黄色粉末
提取部位:叶

有效成分: 漆黄素

Cas号.:528-48-3

规格: 10%,20%,50%,98%

检测方式HPLC

漆黄素

中文别称:非瑟素,漆黄酸,紫铆素,非瑟酮,3,3',4',7-四羟基黄酮

英文名称:Fisetin

分 子 式:C15H10O6

分 子 量:286.24 

C A S号:528-48-3

纯 度:HPLC≥5-98%漆黄素Fisetin

产品外观:黄色针状结晶

熔 点:320-325℃

储存条件:2-8°C,干燥、避光、密封 生产企业:长沙上禾生物

溶 解 性:溶于乙醇、丙酮和醋酸。几乎不溶于水、 、苯、氯仿及石油醚。

提取来源:漆树科植物木腊树Rhus succedanea L

药理药效:抑制前列腺素、.酶抑制、解痉 

漆黄素Fisetin规格:5-98%

以上资料 由长沙上禾生物整理 产品详询:13657416805

漆黄素检测方式:

 

漆黄素(fisetin)检测方法

 

一、色谱条件

色谱柱:Inertsil ODS-3 4.6×150mm  5μm

流动相:乙腈∶水∶磷酸(23∶77∶0.1,V/V)

检测波长:368nm

灵敏度:0.01AUFS

流速:1mL/min

进样量:10μL

柱温:25℃

 

二、溶液制备

  • 对照品溶液制备  精密称取漆黄素对照品约3mg于25mL容量瓶中,用甲醇溶解定容。
  • 样品溶液制备  精密称取样品(含量约10%)50mg于50mL容量瓶中,加约30mL甲醇,超声振荡溶解30min,冷却至室温,用甲醇定容,以0.45μm微孔滤膜过滤,即得。

三、样品测定

    在上述色谱条件下,待仪器稳定,基线平稳后,进样测定,漆黄素保留时间约为20min,含量按外标法计算。

参考文献:

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

  2. 2.

    Li W, Cai JH, Zhang J, Tang YX, Wan L. Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma. Int J Mol Sci. 2012;13:9741–53.

  3. 3.

    Tripathi R, Samadder T, Gupta S, Surolia A, Shaha C. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther. 2011;10:255–68.

  4. 4.

    Suh Y, Afaq F, Johnson JJ, Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis. 2009;30:300–7.

  5. 5.

    Li Z, Guo X, Guan J. An oxygen release system to augment cardiac progenitor cell survival and differentiation under hypoxic condition. Biomaterials. 2012;33:5914–23.

  6. 6.

    Chen WS, Lee YJ, Yu YC, Hsaio CH, Yen JH, Yu SH, Tsai YJ, Chiu SJ. Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin. Int J Radiat Oncol Biol Phys. 2010;77:1527–35.

  7. 7.

    Ying TH, Yang SF, Tsai SJ, Hsieh SC, Huang YC, Bau DT, Hsieh YH. Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8−/caspase-3-dependent pathway. Arch Toxicol. 2012;86:263–73. 

  8. 8.

    Hanneken A, Lin FF, Johnson J, Maher P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci. 2006;47:3164–77.

  9. 9.

    Crozier A, Burns J, Aziz AA, Stewart AJ, Rabiasz HS, Jenkins GI, Edwards CA, Lean ME. Antioxidant flavonols from fruits, vegetables and beverages: measurements and bioavailability. Biol Res. 2000;33:79–88.

  10. 10.

    Higa S, Hirano T, Kotani M, Matsumoto M, Fujita A, Suemura M, Kawase I, Tanaka T. Fisetin, a flavonol, inhibits TH2-type cytokine production by activated human basophils. J Allergy Clin Immunol. 2003;111:1299–306.

  11. 11.

    Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Shih CM, Yang LL. Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol. 2002;76:351–9. 

  12. 12.

    Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2006;9:68–76.

  13. 13.

    Haddad AQ, Fleshner N, Nelson C, Saour B, Musquera M, Venkateswaran V, Klotz L. Antiproliferative mechanisms of the flavonoids 2,2′-dihydroxychalcone and fisetin in human prostate cancer cells. Nutr Cancer. 2010;62:668–81.

  14. 14.

    Chien CS, Shen KH, Huang JS, Ko SC, Shih YW. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem. 2010;333:169–80.

  15. 15.

    Suh Y, Afaq F, Khan N, Johnson JJ, Khusro FH, Mukhtar H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis. 2010;31:1424–33. 

  16. 16.

    Touil YS, Auzeil N, Boulinguez F, Saighi H, Regazzetti A, Scherman D, Chabot GG. Fisetin disposition and metabolism in mice: identification of geraldol as an active metabolite. Biochem Pharmacol. 2011;82:1731–9.

  17. 17.

    Ansó E, Zuazo A, Irigoyen M, Urdaci MC, Rouzaut A, Martínez-Irujo JJ. Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. Biochem Pharmacol. 2010;79:1600–9.

  18. 18.

    Wu MY, Hung SK, Fu SL. Immunosuppressive effects of fisetin in ovalbumin-induced asthma through inhibition of NF-κB activity. J Agric Food Chem. 2011;59:10496–504.

  19. 19.

    Kim JY, Jeon YK, Jeon W, Nam MJ. Fisetin induces apoptosis in Huh-7 cells via downregulation of BIRC8 and Bcl2L2. Food Chem Toxicol. 2010;48:2259–64.

  20. 20.

    Chen Y, Wu Q, Song L, He T, Li Y, Li L, Su W, Liu L, Qian Z, Gong C. Polymeric micelles encapsulating fisetin improve the therapeutic effect in colon cancer. ACS Appl Mater Interfaces. 2015;7:534–42.

  21. 21.

    Chen G, Gao C, Gao X, Zhang DH, Kuan SF, Burns TF, Hu J. Wnt/β-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer. Mol Cancer Ther. 2017. 

  22. 22.

    Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, Lu H, Weir J, El-Bahrawy M, Steel JH, Ghaem-Maghami S, Aboagye EO. The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Res. 2016 Feb;18:1227–46.

  23. 23.

    Echarri GMJ, Green R, Muggia FM. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when. Oncology (Williston Park). 2011;25:156–65. 170

  24. 24.

    Li QQ, Lee RX, Liang H, Zhong Y, Reed E. Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med Oncol. 2013;30:424.

  25. 25.

    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.

  26. 26.

    Khan N, Asim M, Afaq F, Abu ZM, Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res. 2008;68:8555–63.

  27. 27.

    Kozics K, Valovicova Z, Slamenova D. Structure of flavonoids influences the degree inhibition of benzo(a)pyrene - induced DNA damage and micronuclei in HepG2 cells. Neoplasma. 2011;58:516–24. 

  28. 28.

    Katalinić M, Rusak G, Domaćinović BJ, Sinko G, Jelić D, Antolović R, Kovarik Z. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur J Med Chem. 2010;45:186–92. 

  29. 29.

    López-Lázaro M, Willmore E, Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res. 2010;696:41–7.

  30. 30.

    Li J, Cheng Y, Qu W, Sun Y, Wang Z, Wang H, Tian B. Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol. 2011;108:84–93.

  31. 31.

    Khan N, Afaq F, Khusro FH, Mustafa AV, Suh Y, Mukhtar H. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer. 2012;130:1695–705.


Home  |  主打产品  |  植物提取物  |  天然提取物  |  产品目录  |  产品解决方案  |  展会  |  联系我们  |  网站地图  |  手机版
  English     简体版     繁體版
网站首页联系我们网站地图